These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15524492)

  • 1. Clinical and economic impact of epoetins in cancer care.
    Marchetti M; Barosi G
    Pharmacoeconomics; 2004; 22(16):1029-45. PubMed ID: 15524492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.
    Aapro M; San Miguel J
    Oncology; 2004; 67 Suppl 1():17-22. PubMed ID: 15486449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH
    Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
    Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
    BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of chemotherapy-induced anaemia.
    Vansteenkiste J
    Expert Opin Pharmacother; 2003 Dec; 4(12):2221-7. PubMed ID: 14640921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
    Pujade-Lauraine E; Topham C
    Oncology; 2005; 68(2-3):122-9. PubMed ID: 16015034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis.
    Ortega A; Dranitsaris G; Puodziunas AL
    Cancer; 1998 Dec; 83(12):2588-96. PubMed ID: 9874467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythropoietic therapy: cost efficiency and reimbursement.
    Jaspan D
    Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S19-29. PubMed ID: 17687067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Lefebvre P; Vekeman F; Cremieux PY
    Ann Pharmacother; 2010 Mar; 44(3):595; author reply 595-6. PubMed ID: 20179253
    [No Abstract]   [Full Text] [Related]  

  • 20. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.